0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Understanding Causes of Death in Patients With Acute Respiratory Distress Syndrome: A Narrative Review

      review-article
      , MSc 1 , , , MD 2 , , PhD 3 , , PhD 4 , , MD, Fellowship in Critical Care 2 , , MD, Fellowships in Pulmonary and Critical Care 2 , , MD, Fellowships in Medical Informatics, Pulmonary and Critical Care 3
      Critical Care Explorations
      Lippincott Williams & Wilkins
      critical care, death, mortality, respiratory distress syndrome, review

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          OBJECTIVES:

          To provide a comprehensive summary of the published data on cause of death in patients with acute respiratory distress syndrome (ARDS).

          DATA SOURCES:

          PubMed (January 2015 to April 2024), bibliographies of relevant articles, and ARDS Network and Prevention & Early Treatment of Acute Lung Injury (PETAL) network websites.

          STUDY SELECTION:

          Observational studies and clinical trials that reported on cause of death in greater than or equal to 30 patients with ARDS, not obtained from death certificates. Animal studies, case reports, review articles, study protocols, and studies in pediatrics were excluded.

          DATA EXTRACTION:

          Causes of death among ARDS patients who died were extracted and tabulated along with other pertinent study characteristics.

          DATA SYNTHESIS:

          We identified 15 observational studies (nine non-COVID ARDS, five COVID-related ARDS; one both) and five clinical trials (all non-COVID ARDS). Mutually exclusive prespecified categories were used for recording the cause of death in only eight studies although studies differed in the categories included and their definitions. When multiple organ failure was a predetermined category, it was the most common cause of death recorded (~50% of deaths), followed by respiratory causes with proportions varying from 16% to 42% depending on nomenclature (e.g., refractory hypoxemia, pulmonary causes) and definitions. However, the largest observational study in non-COVID ARDS (964 deaths), did not include multiple organ failure as a predetermined category, and found that pulmonary failure (42%) and cardiac failure (37%) were the most common causes of death. In COVID-related ARDS observational studies, pulmonary reasons were the most reported cause of death (up to 88%).

          CONCLUSIONS:

          Few studies have reported cause of death in patients with ARDS. In those that do, cause of death categories and definitions used are heterogeneous. Further research is needed to see whether a more rigorous and unified approach to assigning and reporting cause of death in ARDS would help identify more relevant endpoints for the assessment of targeted treatments in clinical trials.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries.

          Limited information exists about the epidemiology, recognition, management, and outcomes of patients with the acute respiratory distress syndrome (ARDS).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network.

            Traditional approaches to mechanical ventilation use tidal volumes of 10 to 15 ml per kilogram of body weight and may cause stretch-induced lung injury in patients with acute lung injury and the acute respiratory distress syndrome. We therefore conducted a trial to determine whether ventilation with lower tidal volumes would improve the clinical outcomes in these patients. Patients with acute lung injury and the acute respiratory distress syndrome were enrolled in a multicenter, randomized trial. The trial compared traditional ventilation treatment, which involved an initial tidal volume of 12 ml per kilogram of predicted body weight and an airway pressure measured after a 0.5-second pause at the end of inspiration (plateau pressure) of 50 cm of water or less, with ventilation with a lower tidal volume, which involved an initial tidal volume of 6 ml per kilogram of predicted body weight and a plateau pressure of 30 cm of water or less. The primary outcomes were death before a patient was discharged home and was breathing without assistance and the number of days without ventilator use from day 1 to day 28. The trial was stopped after the enrollment of 861 patients because mortality was lower in the group treated with lower tidal volumes than in the group treated with traditional tidal volumes (31.0 percent vs. 39.8 percent, P=0.007), and the number of days without ventilator use during the first 28 days after randomization was greater in this group (mean [+/-SD], 12+/-11 vs. 10+/-11; P=0.007). The mean tidal volumes on days 1 to 3 were 6.2+/-0.8 and 11.8+/-0.8 ml per kilogram of predicted body weight (P<0.001), respectively, and the mean plateau pressures were 25+/-6 and 33+/-8 cm of water (P<0.001), respectively. In patients with acute lung injury and the acute respiratory distress syndrome, mechanical ventilation with a lower tidal volume than is traditionally used results in decreased mortality and increases the number of days without ventilator use.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

              There is no proven specific pharmacological treatment for patients with the acute respiratory distress syndrome (ARDS). The efficacy of corticosteroids in ARDS remains controversial. We aimed to assess the effects of dexamethasone in ARDS, which might change pulmonary and systemic inflammation and result in a decrease in duration of mechanical ventilation and mortality.
                Bookmark

                Author and article information

                Contributors
                Journal
                Crit Care Explor
                Crit Care Explor
                CC9
                Critical Care Explorations
                Lippincott Williams & Wilkins (Hagerstown, MD )
                2639-8028
                22 August 2024
                September 2024
                : 6
                : 9
                : e1147
                Affiliations
                [1 ] EpiMed Communications, Abingdon, United Kingdom.
                [2 ] Research & Development, Bayer AG, Berlin, Germany.
                [3 ] Integrated Evidence Generation, Bayer AG, Berlin, Germany.
                [4 ] New Product Portfolio, Bayer AG, Berlin, Germany.
                Author notes
                For information regarding this article, E-mail: susan.bromley@ 123456epimed.co.uk
                Author information
                https://orcid.org/0000-0003-4630-9823
                Article
                CCE-D-23-00519 00002
                10.1097/CCE.0000000000001147
                11343544
                39172623
                d6f844e7-a70d-4398-8904-f91f46a040b1
                Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.

                This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

                History
                Funding
                Funded by: Bayer, doi 10.13039/100004326;
                Award ID: Not applicable
                Award Recipient : Not Applicable
                Categories
                Narrative Review
                Custom metadata
                TRUE
                T

                critical care,death,mortality,respiratory distress syndrome,review

                Comments

                Comment on this article